

GenCore version 5.1.6
 Copyright (c) 1993 - 2003 Compugen Ltd.
 OM protein - protein search, using sw model

Run on: May 29, 2003, 15:21:08 ; search time 69 Seconds
 (without alignments)
 156.425 Million cell updates/sec

Title: US-09-924-102-2
 Perfect score: 81

Sequence: 1 MLLSTHLFTLYFLFVLSL.....RWGGQGGRRGTAATGGMFLS 81

Scoring table: OLIGO

Gapop 60.0 , Gapext 60.0

Searched: 908470 seqs, 133250620 residues

Word size : 0

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database : A_Geneseq_101002:*

1: /SIDS2/gcdata/geneseq/geneseq/geneseqp-emb1/AA1980.DAT:*

2: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1981.DAT:*

3: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1982.DAT:*

4: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1983.DAT:*

5: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1984.DAT:*

6: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1985.DAT:*

7: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1986.DAT:*

8: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1987.DAT:*

9: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1988.DAT:*

10: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1989.DAT:*

11: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1990.DAT:*

12: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1991.DAT:*

13: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1992.DAT:*

14: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1993.DAT:*

15: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1994.DAT:*

16: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1995.DAT:*

17: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1996.DAT:*

18: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1997.DAT:*

19: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1998.DAT:*

20: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1999.DAT:*

21: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA2000.DAT:*

22: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA2001.DAT:*

23: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

RESULT 1

ID AAE19840
 AAEL9840 standard; Protein; 81 AA.

XX AAE19840;

AC AAE19840;

XX DE Human homologue of Drosophila melanogaster reaper protein (hRpr).

XX KW Human; reaper protein; Rpr; detection; purification; screening; therapy; tumour; cytostatic; protein.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT Region 5..17

FT Region /label= Alpha_helix

FT Region .23..42

FT Region /label= Alpha_helix

FT Misc-difference 38

FT /note= "Encoded by AAA"

FT Region 43..55

FT Region /label= Alpha_helix

XX PD 14-FEB-2002.

XX PF 08-AUG-2001; 2001WO-US24765.

XX PR 08-AUG-2000; 2000US-223999P.

XX

Summaries

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result No.	Score	Query Match Length	DB ID	Description
1	81	100.0	81 23 AAE19840	Human homologue of Human hRpr derived Human secreted pro Human polypeptide Human G protein-co Novel G protein co Human secreted pro Human immune/haema Human polypeptide
2	17	21.0	20 23 AAE19842	
3	11	13.6	71 21 AAG02507	
4	10	12.3	117 22 AA002957	
5	10	12.3	181 22 ABU29487	
6	10	12.3	181 23 ABG60775	
7	9	11.1	29 21 AAB34577	
8	9	11.1	39 22 AAM65158	
9	9	11.1	43 22 AAO12138	
10	9	11.1	57 23 ABP10360	

Human ORF protein

PA (UYDU-) UNIV DUKE.
 XX Kornbluth SA, Holley C;
 PI WPI; 2002-241769/29.
 DR N-PDB; AAC31598.

XX New human homologue of *Drosophila melanogaster reaper protein (hrpr)*, can be useful for generating antibodies and for screening compounds, which can inhibit or enhance hrpr activity

PS Claim 1; Fig 1; 45pp; English.

XX The invention relates to human homologue of *Drosophila melanogaster Reaper protein (hrpr)* and its corresponding nucleic acid. The hrpr polypeptides are useful for generating antibodies, which can be used in detection or purification protocols designed to detect or purify the polypeptide to which the antibody is directed. These sequences are also used for screening compounds, which can enhance or inhibit hrpr and for treating tumours. The hrpr polynucleotides are useful as a probe or primer. The present sequence is human homologue of *Drosophila melanogaster reaper protein (hrpr)*.

SQ Sequence 81 AA;

Query Match	100.0%	Score 81;	DB 23;	Length 81;
Best Local Similarity	100.0%	Pred. No.	3.2e-77	
Matches	81;	Conservative	0;	Mismatches
			0;	Indels
			0;	Gaps

Qy 1 MLLSHLFIYFLIVFLYSIGLDRARLCLRKTKQQQKEQQLRQSEVLFSETLRKGKG 60
 Db 1 MLLSHLFIYFLIVFLYSIGLDRARLCLRKTKQQQKEQQLRQSEVLFSETLRKGKG 60

Qy 61 RRWGGQGGGGTADGGGMFLS 81
 Db 61 RRWGGQGGGGTADGGGMFLS 81

RESULT 2

ID AAE19842
 ID AAE19842 standard; peptide; 20 AA.

AC AAE19842;
 XX DT 18-JUN-2002 (first entry)
 DE Human secreted protein.

XX Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation; gene therapy; chromosome mapping.

XX OS Homo sapiens.
 PN EP1033401-A2.

PD 06-SEP-2000. *Not ant*

XX PR 21-FEB-2000; 2000EP-0200610.

XX PR 26-FEB-1999; 99US-0122487.

PA (GEST) GENSET.

XX PT Dumas Milne Edwards J, Ducleart A, Giordano J;

XX DR WPI; 2000-50038145.
 DR N-PDB; AAC02513.

XX PT New nucleic acid that is a 5' expressed sequence tag (5' EST) for obtaining cDNAs that correspond to 5' ESTs and for diagnostic, forensic, gene therapy and chromosome mapping procedures

XX PS Claim 13; SEQ ID 6588; 71pp + CD-ROM; English.

XX The present sequence is a polypeptide encoded by one of a large number of 5' ESTs derived from mRNAs encoding secreted proteins. The 5' ESTs were prepared from total human RNAs or polyA+ RNAs derived from 30 different tissues. EST sequences usually correspond mainly to the 3' untranslated region (UTR) of the mRNA because they are often obtained from oligo-dT primed cDNA libraries. Such ESTs are not well suited for isolating cDNA sequences derived from the 5' ends of mRNAs and even in those cases where longer cDNA sequences have been obtained, the 5' UTR is rarely included. 5' ESTs are derived from mRNAs with intact 5' ends and can therefore be used to obtain full length cDNAs and genomic DNAs. 5' ESTs are also used in diagnostic, forensic, gene therapy and chromosome mapping procedures. They are used to obtain upstream regulatory sequences and to design expression and secretion vectors.

SQ Sequence 71 AA;

Query Match 13.6%; Score 11; DB 21; Length 71;
 Best Local Similarity 100.0%; Pred. No. 0.00073; Mismatches 0; Indels 0; Gaps 0;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 LFIYIYIYIYFLS 17
 Db 14 LFIYIYIYIYFLS 24

RESULT 4
 AAU02957
 ID AAU02957 standard; Protein: 117 AA.
 XX
 AC AAU02957;
 XX 06-NOV-2001 (first entry)
 DE Human polypeptide SEQ ID NO 16849.
 XX
 KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
 KW vaccine; peptide therapy; stem cell growth factor; haemopoiesis;
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;
 KW nervous system disorders; arthritis; inflammation.
 XX
 OS Homo sapiens.
 XX
 PN WO200168835-A2.
 XX
 PD 07-SEP-2001.
 XX
 PF 26-FEB-2001; 2001WO-US04927.
 XX
 PR 28-FEB-2000; 2000US-0515126.
 PR 18-MAY-2000; 2000US-0577409.
 XX
 PA (HYSEQ-) HYSEQ INC.
 XX
 PT Tang YT, Liu C, Drmanac RT;
 PI
 DR WPI: 2001-514838/56.
 DR N-FSDB; RAI182888.

XX
 PT Isolated nucleic acids and polypeptides, useful for preventing
 PT diagnosing and treating e.g. leukaemia, inflammation and immune
 PT disorders -

XX
 PS Claim 20: SEQ ID NO 16849; 1399pp + Sequence Listing; English.

XX
 CC The invention relates to human polynucleotides (AAI7991-AAI9341) and
 CC the encoded proteins (AA00010-AA013910) that exhibit activity relating to
 CC cytokine, cell proliferation or cell differentiation or which may induce
 CC production of other cytokines in other cell populations. The
 CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
 CC peptide therapy. The polypeptides have various cytokine-like activities,
 CC e.g. stem cell growth factor activity, haematopoiesis regulating
 CC activity, tissue growth factor activity, immunomodulatory activity and
 CC activity/inhibit activity and may be useful in the diagnosis and/or
 CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
 CC inflammation.
 Note: The sequence data for this patient did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences.

CC Sequence 117 AA;

Query Match 12.3%; Score 10; DB 22; Length 117;
 Best Local Similarity 100.0%; Pred. No. 0.013; Mismatches 0; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 19 SLGDRARLIC 28
 Db 15 SLGDRARLIC 24

RESULT 5
 AAU29487
 ID AAU29487 standard; Protein: 181 AA.
 XX
 AC AAU29487;
 XX
 DT 18-DEC-2001 (first entry)
 DE Human G protein-coupled receptor (GPCR) polypeptide #108.
 XX
 KW Human; G protein-coupled receptor; GPCR; mental disorder; schizophrenia;
 KW neurological disorder; metabolic disorder; cancer; rheumatoid arthritis;
 KW thyroid disorder; neurodegenerative disorder; cardiovascular disorder; HIV;
 KW renal failure; autoimmune disorder; hyperproliferative disorder; human immunodeficiency virus; viral infection; neuroprotective; KW immunostimulant; neuroleptic; nootropic; tranquiliser; antidepressant;
 KW anorectic; gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN WO200168858-A2.
 XX
 PD 20-SEP-2001.
 XX
 PF 16-MAR-2001; 2001WO-US049456.
 XX
 PR 16-MAR-2000; 2000US-187783P.
 PR 16-MAR-2000; 2000US-18907P.
 PR 16-MAR-2000; 2000US-189917P.
 PR 16-MAR-2000; 2000US-189918P.
 PR 16-MAR-2000; 2000US-189960P.
 PR 29-MAR-2000; 2000US-192155P.
 PR 29-MAR-2000; 2000US-192234P.
 PR 29-MAR-2000; 2000US-192430P.
 PR 29-MAR-2000; 2000US-192433P.
 PR 29-MAR-2000; 2000US-192434P.
 PR 29-MAR-2000; 2000US-192945P.
 XX
 PA (PHAG-) PHARMACIA & UPJOHN CO.
 XX
 PT Vogeli G;
 XX
 DR WPI: 2001-607458/69.
 DR N-PSDB; RAS46526.

XX
 PT Nucleic acid encoding G protein-coupled receptors, useful for the
 PT prevention, diagnosis and treatment of mental disorders -

XX
 PS Claim 31; Page 94; 274pp; English.

XX
 CC Sequences AAU9380-AAU29509 represent human G protein-coupled receptor
 CC (GPCR) polypeptides of the invention. The proteins and the DNA sequences
 CC encoding them can be used to identify compounds which bind to GPCR
 CC polypeptides and in screening for compounds that modulate GPCR activity.
 CC By screening a human subject for the presence of mutations in GPCR DNA, a
 CC GPCR-related disorder or a genetic predisposition can be diagnosed. The
 CC sequences can also be used for treatment and prevention of mental
 CC disorders such as schizophrenia, neurologic disorders such as manic
 CC depression, metabolic disorders such as obesity, cancer, rheumatoid
 CC arthritis, thyroid disorders such as myxoedema, neurodegenerative
 CC disorders such as Parkinson's disease, cardiovascular disorders such as
 CC atherosclerosis, renal failure, autoimmune disorders, hyperproliferative
 CC disorders such as psoriasis and viral infections such as those caused by
 CC HIV.

XX
 SQ Sequence 181 AA;

Query Match 12.3%; Score 10; DB 22; Length 181;
 Best Local Similarity 100.0%; Pred. No. 0.018; Mismatches 0; Indels 0; Gaps 0;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 19 SLGDRARICL 28
 CC |||||||
 CC 1 SLGDRARICL 10

Db

RESULT 6

ID ABG60775
 ABG60775 standard; Protein; 181 AA.

XX AC ABG60775;
 XX DT 13-AUG-2002 (first entry)

DE Novel G protein coupled receptor (nGPCR-x) #108.

XX KW G protein coupled receptor; nGPCR-x; immune response; thyroid disorder; mental disorder; thyrotoxicosis; myxoedema; inflammatory condition; Crohn's disease; cell differentiation; homeostasis; rheumatoid arthritis; renal failure; autoimmune disorder; movement disorder; CNS disorder; viral infection; human immunodeficiency virus; HIV; metabolic disorder; cardiovascular disorder; diabetes; obesity; anorexia; cardiomopathy; porliferative disease; cancer; psoriasis; lung cancer; hormonal disorder; sexual dysfunction.

XX OS Homo sapiens.

PN US2002058306-A1.

XX PD 16-MAY-2002.

XX PF 16-MAR-2001; 2001NS-0811284.

XX PR 16-MAR-2000; 2000NS-189783.

PR 16-MAR-2000; 2000NS-189907P.

PR 16-MAR-2000; 2000NS-189917P.

PR 16-MAR-2000; 2000NS-189918P.

PR 16-MAR-2000; 2000NS-189960P.

PR 24-MAR-2000; 2000NS-192155P.

PR 27-MAR-2000; 2000NS-192234P.

PR 29-MAR-2000; 2000NS-192830P.

PR 29-MAR-2000; 2000NS-192945P.

PR 29-MAR-2000; 2000NS-192916P.

PR 29-MAR-2000; 2000NS-192923P.

PR 29-MAR-2000; 2000NS-192930P.

PR 29-MAR-2000; 2000NS-192945P.

PR 29-MAR-2000; 2000NS-192830P.

PR 29-MAR-2000; 2000NS-192945P.

XX (VOGE/) VOGELI G.

PI Vogeli G;

XX WPI; 2002-434856/16.

DR N-PSDB; ABK81704.

XX PS Claim 27; Page 72; 216pp; English.

CC The invention describes an isolated nucleic acid (I) comprising a sequence encoding a portion of a G protein coupled receptor (nGPCR-x).
 CC (I) is used to produce a recombinant nGPCR-x polypeptide. A polypeptide encoded by (I) is used to induce an immune response in a mammal. nGPCR-x is used to identify a compound that binds to it and/or modulates its activity. (I) is used to identify animal homologues of nGPCR-x. (I) can be used to diagnose a human subject as having a brain or genetic predisposition disorder, such as a mental disorder. (I) is used to screen for an nGPCR-x related disorder including thyroid disorders (e.g. thyrotoxicosis, myxoedema), renal failure, inflammatory conditions (e.g.

CC CC Crohn's disease), diseases related to cell differentiation and homeostasis, rheumatoid arthritis, autoimmune disorders, movement disorders, CNS disorders, viral infections (e.g. Human immunodeficiency virus), metabolic and cardiovascular disorders (e.g. diabetes, obesity, anorexia, cardiomopathies), proliferative diseases and cancers (e.g. psoriasis, lung cancer), hormonal disorders, sexual dysfunction and hereditary mental disorders in a human patient. A host cell comprising (I) is used to screen for a modulator of nGPCR-x activity. nGPCR-x is used to identify compounds that can treat mental disorders. The polypeptide encoded by (I) is used to purify a G protein from a sample. This is the amino acid sequence of a novel G protein coupled receptor (nGPCR-x) protein described in the invention.

CC CC Sequence 181 AA;

CC SQ

QY 19 SLGDRARICL 28
 CC |||||||
 CC 1 SLGDRARICL 10

Db

RESULT 7

ID RAB34577
 AAB34577 standard; Protein; 29 AA.

XX AC AAB34577;

XX DT 26-JAN-2001 (first entry)

XX DE Human secreted protein sequence encoded by gene 1 SEQ ID NO:61.

XX KW Human; secreted protein; diagnosis; immunosuppressive; antiarhythmic; antirheumatic; antiprofertive; cytostatic; cardiant; vasotropic; cerebroprotective; nootropic; neuroprotective; antibacterial; virucide; fungicide; ophthalmologic; gene therapy; autoimmune disease; neoplasm; hyperproliferative disorder; cancer; cardiovascular disorder; infection; cerebrovascular disorder; angiogenesis; nervous system disorder; ocular disorder; wound healing; skin aging; food additive; preservative.

XX OS Homo sapiens.

PN WO200056751-A1.

XX PD 28-SEP-2000.

XX PF 09-MAR-2000; 2000W0-0506013.

XX PR 19-MAR-1999; 9901S-0125360.

PR 11-JUN-1999; 9901S-0138626.

PR 03-DEC-1999; 9901S-0168662.

XX PA (HUMA-) HUMAN GENOME SCI INC.

XX PI Rosen CA, Ruben SM, Komatsoulis G;

XX DR WPI; 2000-579482/54.

XX DR N-PSDB; AAC59738.

XX PS Isolated nucleic acid molecule encoding a human secreted protein is used in preventing, treating or ameliorating a medical condition.

XX PS Claim 11; Page 371; 419pp; English.

XX The polynucleotide sequences given in AAC59738 to AAC59707 encode the human secreted proteins given in AAB4577 to AAB34626. AAB34627 to AAB34686 represent human secreted polypeptide sequences and proteins homologous to them, which are given in the exemplification of the present invention. Human secreted proteins have activities based on the tissues and cells the genes are expressed in. Example of activities include: antiarthritic; immunosuppressive; antirheumatic; antiproliferative;

CC cytostatic; cardiot; vaso tropic; cerebroprotective; nootropic;
 CC neuroprotective; antibacterial; virucide; fungicide; and
 CC ophthalmological. The Polynucleotides and proteins can be are used to
 prevent, treat or ameliorate a medical condition in e.g. humans, mice,
 rabbits, goats, horses, cats, dogs, chickens or sheep. They are also
 used in diagnosing a pathological condition or susceptibility to a
 pathological condition. Disorders which are diagnosed or treated include
 CC autoimmune diseases, hyperproliferative disorders e.g. neoplasms and
 CC cancers of the breast or liver, cardiovascular disorders
 CC cerebrovascular disorders, angiogenesis, nervous system disorders,
 CC infections caused by bacteria, viruses and fungi and ocular disorders.
 The proteins can also be used to aid wound healing and epithelial cell
 CC proliferation, to prevent skin aging due to sunburn, to maintain organs
 before transplantation, for supporting cell culture of primary tissues,
 CC to regenerate tissues and in chemotaxis. The proteins can also be used
 as a food additive or preservative to increase or decrease storage
 CC capabilities. AAC9729 to AAC5973 and AA34576 represent sequences used
 CC in the exemplification of the present invention.

SQ Sequence 29 AA;

Query Match 11.1%; Score 9; DB 21; Length 29;
 Best Local Similarity 100.0%; Pred. No. 0.043; Mismatches 0; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 LFTYVLFYF 15
 ID ||||||| 1
 DB 18 LFTYVLFYF 26

RESULT 8
 XX AAM85158
 XX AAM85158 standard; Protein; 39 AA.

AC AAM85158;
 XX
 DT 07-NOV-2001 (first entry)
 XX Human immune/haematopoietic antigen SEQ ID NO:12751.

KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
 KW cytostatic; gene therapy; vaccine; metastasis.
 OS Homo sapiens.
 XX
 PN WO201517182-A2.
 XX
 PD 09-AUG-2001.
 XX
 PF 17-JAN-2001; 2001IWO-US01354.
 XX
 PR 31-JAN-2000; 2000US-0179065.
 PR 04-FEB-2000; 2000US-0180628.
 PR 24-FEB-2000; 2000US-0184664.
 PR 02-MAR-2000; 2000US-0186350.
 PR 16-MAR-2000; 2000US-0189874.
 PR 17-MAR-2000; 2000US-0190076.
 PR 18-APR-2000; 2000US-0198123.
 PR 19-MAY-2000; 2000US-0205515.
 PR 07-JUN-2000; 2000US-0209467.
 PR 28-JUN-2000; 2000US-0214886.
 PR 30-JUN-2000; 2000US-0215135.
 PR 07-JUL-2000; 2000US-0216647.
 PR 07-JUL-2000; 2000US-0224518.
 PR 14-AUG-2000; 2000US-0224519.
 PR 14-AUG-2000; 2000US-0225213.
 PR 14-AUG-2000; 2000US-0225214.

PR 14-AUG-2000; 2000US-0225266.
 PR 14-AUG-2000; 2000US-0225267.
 PR 14-AUG-2000; 2000US-0225268.
 PR 14-AUG-2000; 2000US-0225270.
 PR 14-AUG-2000; 2000US-0225447.
 PR 14-AUG-2000; 2000US-0225757.
 PR 14-AUG-2000; 2000US-0225758.
 PR 14-AUG-2000; 2000US-0225759.
 PR 18-AUG-2000; 2000US-0226279.
 PR 22-AUG-2000; 2000US-0226681.
 PR 22-AUG-2000; 2000US-0226868.
 PR 22-AUG-2000; 2000US-0227182.
 PR 23-AUG-2000; 2000US-0227009.
 PR 30-AUG-2000; 2000US-0228924.
 PR 01-SEP-2000; 2000US-0229287.
 PR 01-SEP-2000; 2000US-0229343.
 PR 01-SEP-2000; 2000US-0229344.
 PR 01-SEP-2000; 2000US-0229345.
 PR 05-SEP-2000; 2000US-0229509.
 PR 05-SEP-2000; 2000US-0229513.
 PR 06-SEP-2000; 2000US-0230437.
 PR 08-SEP-2000; 2000US-0231242.
 PR 08-SEP-2000; 2000US-0231243.
 PR 08-SEP-2000; 2000US-0231413.
 PR 08-SEP-2000; 2000US-0231414.
 PR 08-SEP-2000; 2000US-02322080.
 PR 08-SEP-2000; 2000US-02322081.
 PR 12-SEP-2000; 2000US-0231968.
 PR 14-SEP-2000; 2000US-0232397.
 PR 14-SEP-2000; 2000US-0232398.
 PR 14-SEP-2000; 2000US-0234223.
 PR 14-SEP-2000; 2000US-0234274.
 PR 14-SEP-2000; 2000US-02344997.
 PR 14-SEP-2000; 2000US-0233063.
 PR 14-SEP-2000; 2000US-0233064.
 PR 14-SEP-2000; 2000US-0233065.
 PR 21-SEP-2000; 2000US-0234223.
 PR 25-SEP-2000; 2000US-02344997.
 PR 14-SEP-2000; 2000US-0234998.
 PR 26-SEP-2000; 2000US-0234984.
 PR 27-SEP-2000; 2000US-0235834.
 PR 27-SEP-2000; 2000US-0235836.
 PR 29-SEP-2000; 2000US-0236327.
 PR 29-SEP-2000; 2000US-0236367.
 PR 29-SEP-2000; 2000US-0236368.
 PR 29-SEP-2000; 2000US-0236369.
 PR 29-SEP-2000; 2000US-0236370.
 PR 02-OCT-2000; 2000US-0236802.
 PR 02-OCT-2000; 2000US-0237037.
 PR 02-OCT-2000; 2000US-0237038.
 PR 02-OCT-2000; 2000US-0237039.
 PR 02-OCT-2000; 2000US-0237040.
 PR 13-OCT-2000; 2000US-0237935.
 PR 13-OCT-2000; 2000US-0239937.
 PR 20-OCT-2000; 2000US-0240950.
 PR 20-OCT-2000; 2000US-0241221.
 PR 20-OCT-2000; 2000US-0241785.
 PR 20-OCT-2000; 2000US-0241786.
 PR 20-OCT-2000; 2000US-0241787.
 PR 20-OCT-2000; 2000US-0241808.
 PR 20-OCT-2000; 2000US-0241809.
 PR 01-NOV-2000; 2000US-0244617.
 PR 08-NOV-2000; 2000US-0246474.
 PR 08-NOV-2000; 2000US-0246475.
 PR 08-NOV-2000; 2000US-0246476.
 PR 08-NOV-2000; 2000US-0246477.
 PR 08-NOV-2000; 2000US-0246523.
 PR 08-NOV-2000; 2000US-0246524.

SQ	Sequence	39 AA;
PR	08-NOV-2000;	20000US-0245525.
PR	08-NOV-2000;	20000US-0245526.
PR	08-NOV-2000;	20000US-0245527.
PR	08-NOV-2000;	20000US-0245528.
PR	08-NOV-2000;	20000US-0245532.
PR	08-NOV-2000;	20000US-0245609.
PR	08-NOV-2000;	20000US-0246110.
PR	08-NOV-2000;	20000US-0246111.
PR	08-NOV-2000;	20000US-0246113.
PR	17-NOV-2000;	20000US-0249207.
PR	17-NOV-2000;	20000US-0249208.
PR	17-NOV-2000;	20000US-0249210.
PR	17-NOV-2000;	20000US-0249211.
PR	17-NOV-2000;	20000US-0249212.
PR	17-NOV-2000;	20000US-0249213.
PR	17-NOV-2000;	20000US-0249214.
PR	17-NOV-2000;	20000US-0249215.
PR	17-NOV-2000;	20000US-0249216.
PR	17-NOV-2000;	20000US-0249217.
PR	17-NOV-2000;	20000US-0249218.
PR	17-NOV-2000;	20000US-0249244.
PR	17-NOV-2000;	20000US-0249245.
PR	01-DEC-2000;	20000US-0250391.
PR	05-DEC-2000;	20000US-0250390.
PR	05-DEC-2000;	20000US-0251988.
PR	05-DEC-2000;	20000US-0251979.
PR	05-DEC-2000;	20000US-0251479.
PR	08-DEC-2000;	20000US-0250856.
PR	08-DEC-2000;	20000US-0250868.
PR	08-DEC-2000;	20000US-0250869.
PR	08-DEC-2000;	20000US-0251989.
PR	11-DEC-2000;	20000US-0250990.
PR	05-JAN-2001;	2001US-0259678.
PA	(HUMA-) HUMAN GENOME SCI INC.	
XX	Rosen CA, Barash SC, Ruben SM;	
XX	WPI: 2001-483/26/52.	
DR	N-PSDB; AAK5939.	
XX	Nucleic acids encoding human immune/hematopoietic antigen polypeptides, useful for preventing, diagnosing and/or treating cancers and metastasis -	
PS	Claim 11; SEQ ID NO 12751; 3071pp + Sequence Listing; English.	
XX	AAK4510 to AAK64702 encode the human immune/hematopoietic antigen (I) amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic activity, and can be used in gene therapy and vaccine production. (I) proteins and polynucleotides may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate (I) expression. For example, they may be used to treat disorders associated with decreased expression by rectifying mutations or deletions in a patient's genome that affect the activity of (I) by expressing inactive proteins or to supplement the patients own production of (I). Additionally, (I) polynucleotides may be used to produce the secreted (I), by inserting the nucleic acids into a host cell and culturing the cell to express the protein. (I) proteins and polynucleotides may be used to prevent, diagnose and treat immune/hematopoietic-related diseases, especially cancer and cancer metastases of haematopoietic-derived cells. AAK64703 to AAK87694 represent human immune/hematopoietic antigen genomic sequences from the present invention. AAK5942 to AAK54950 and AAM82169 represent sequences used in the exemplification of the present invention.	
CC	Query Match 11.1%; Score 9; DB 22; Length 43; Best Local Similarity 100.0%; Pred. No. 0.05%; Mismatches 0; Indels 0; Gaps 0;	QY 19 SIGDRARLC 27
CC	Best Local Similarity 100.0%; Pred. No. 0.05%; Mismatches 0; Indels 0; Gaps 0;	QY 26 SIGDRARLC 34
CC	RESULT 9	
CC	AA012138	
CC	ID AA012138 standard; Protein; 43 AA.	
CC	XX	
CC	AA012138;	
CC	XX	
CC	06-NOV-2001 (first entry)	
CC	XX	
CC	Human polypeptide SEQ ID NO 26030.	
CC	DE	
CC	Human; cytokine; cell proliferation; cell differentiation; gene therapy; vaccine; peptide therapy; stem cell growth factor; haematopoiesis; tissue growth factor; immunomodulatory; cancer; leukaemia; nervous system disorders; arthritis; inflammation.	
CC	XX	
CC	OS Homo sapiens.	
CC	XX	
CC	W0200164835-A2.	
CC	XX	
CC	PD 07-SEP-2001.	
CC	XX	
CC	PF 26-FEB-2001; 2001WO-US04927.	
CC	XX	
CC	PR 28-FEB-2000; 20000US-0515126.	
CC	XX	
CC	PR 18-MAY-2000; 20000US-0577409.	
CC	XX	
CC	PA (HYSE-) HYSEQ INC.	
CC	XX	
CC	PI Tang YT, Liu C, Drmanac RT;	
CC	XX	
CC	DR WPI: 2001-514838/56.	
CC	DR N-PSDB; AAM92069.	
CC	XX	
CC	Isolated nucleic acids and polypeptides, useful for preventing, diagnosing and treating e.g. leukaemia, inflammation and immune disorders -	
CC	XX	
CC	PS Claim 20; SEQ ID NO 26030; 1399pp + Sequence Listing; English.	
CC	XX	
CC	The invention relates to human polynucleotides (AII79941-AII93841) and the encoded proteins (AA000010-AA013910) that exhibit activity relating to cytokine, cell proliferation or cell differentiation or which may induce production of other cytokines in other cell populations. The polynucleotides and polypeptides are useful in gene therapy, vaccines or peptide therapy. The polypeptides have various cytokine-like activities, e.g. stem cell growth factor activity, haematopoiesis regulating activity, tissue growth factor activity, immunomodulatory activity and activin/inhibin activity and may be useful in the diagnosis and/or treatment of cancer, leukaemia, nervous system disorders, arthritis and inflammation.	
CC	CC Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from Wipo at http://wipo.int/pub/published-pct_sequences .	
CC	CC	
CC	CC	
CC	XX	
CC	Sequence 43 AA;	
CC	Query Match 11.1%; Score 9; DB 22; Length 43; Best Local Similarity 100.0%; Pred. No. 0.05%; Mismatches 0; Indels 0; Gaps 0;	QY 7 IIFYLFLYF 15

DB 3 LFIYLFIYF 11

RESULT 10

ABP10360

ID ABP10360 standard; Protein; 57 AA.

XX

AC

XX

DT

24-JUN-2002 (first entry)

XX

DE Human ORFX protein sequence SEQ ID NO:20702.

XX

KW Human; open reading frame; ORFX; gene; therapy; cancer; cirrhosis; hyperproliferative disorder; psoriasis; benign tumour; haemorrhage; degenerative disorder; osteoarthritis; neurodegenerative disorder; cardiovascular disease; diabetes mellitus; systemic lupus erythematosus; hypertension; hypothyroidism; cholesterol ester storage disease; immune deficiency; immune disorder; infectious disease; autoimmune disorder; rheumatoid arthritis; autoimmune thyroditis; myasthenia gravis.

XX

OS Homo sapiens.

PN WO200192523-A2.

XX

PD 06-DEC-2001.

XX

PF 29-MAY-2001; 2001WO-US10836.

XX

PR 30-MAY-2000; 2000US-206132P.

XX

PR 29-AUG-2000; 2000US-228716P.

XX

PA (CURA-) CURAGEN CORP.

XX

PI Shinkets RA, Leach MD;

XX

PT Novel human polypeptides and polynucleotides useful for diagnosing, preventing and treating cardiovascular disease, neurodegenerative, hyperproliferative disorders and autoimmune disorders

XX

PS Disclosure; SBQ ID 20702; 1037PP; English.

XX

CC The present invention describes substantially purified human proteins (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1 in the specification). ABN15762 to ABN2752 encode the human ORFX proteins given in ABP00010 to ABP11500. ORFX proteins are useful for treating or preventing a pathology associated with an ORFX-associated disorder in humans, and in the manufacture of a medicament for treating a syndrome associated with ORFX-associated disorder. ORFX polynucleotide sequences can be used in gene therapy. ORFX sequences can be used in the treatment of cancer, hyperproliferative disorders, cirrhosis of liver, psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage, osteoarthritis, neurodegenerative disorders, disorders related to organ transplantation, cardiovascular diseases, diabetes mellitus, systemic lupus erythematosus, hypertension, hypothyroidism, cholesterol ester storage disease, various immune deficiencies and disorders, infectious diseases, autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. ORFX proteins are also useful for treating burns, incisions, ulcers, for treating osteoporosis, bone degenerative disorders, or periodontal disease, and for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues and conditions resulting from systemic cytokine damage.

N.B. The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp://wipo.int/pub/published_pct_sequences.

XX

Query Match 11.1%; Score 9; DB 23; Length 57;

Best Local Similarity 100.0%; Pred. No. 0.076; Mismatches 0;

Matches 9; Conservative 0; Indels 0; Gaps 0;

QY 7 LFIYLFIYF 15

Db 40 LFIYLFIYF 48

RESULT 11

AAB8270

ID AAB8270 standard; Protein; 77 AA.

XX

AC AAB8270;

XX

DT 14-MAR-2001 (first entry)

XX

DE Lung cancer associated polypeptide sequence SEQ ID 608.

XX

KW Human; lung cancer associated protein; neuroprotective; cytostatic; cardioactive; immunomodulatory; muscular active; vulnerary; gastrointestinal; nephrotropic; antiinfective; gynecological; antibacterial; diagnosis; neural disorder; immune disorder; reproductive; proliferative disorder; wound healing; infectious disease.

XX

OS Homo sapiens.

XX

PN WO200055180-A2.

XX

PD 21-SEP-2000.

XX

PR 08-MAR-2000; 2000WO-US05918.

XX

PR 12-MAR-1999; 99US-0124270.

XX

PA (HUMA-) HUMAN GENOME SCI INC.

XX

PA (ROSE/) ROSEN C A.

XX

PI Rubin SM;

XX

DR WPI; 2000-587314/55.

XX

DR N-PDB; AAF18146.

XX

PT Lung cancer associated gene sequences, referred to as lung cancer

PT

PT antigens, useful for treatment, prevention, and diagnosis of disorders

XX

PT such as lung cancer -

CC sequences (claim 11; Page 110; 1425pp; English).

XX

PS

CC Polynucleotide sequences AAF17982 - AAF18424 encode human lung cancer

CC associated proteins represented in ABP58105 - ABP5858. Lung cancer

CC associated proteins and polynucleotide sequences, their agonists, and

CC antagonists may have neuroprotective; cytostatic; cardioactive;

CC immunomodulatory; muscular active general; pulmonary; gastrointestinal

CC general; nephrotropic; antiinfective; gynecological; or antibacterial

CC activity. The invention also includes antibodies specific for the

CC protein or polynucleotide sequences. The lung cancer associated

CC polynucleotide sequences may be used for detection of lung cancer,

CC chromosome identification, as chromosome markers, and for numerous other

CC diagnostic or research purposes. The proteins may be used to treat

CC disorders such as neural, immune, muscular, reproductive,

CC gastrointestinal, pulmonary, cardiovascular, renal, and proliferative

CC disorders. The proteins may also be used in the treatment of wounds and

CC infectious diseases. Polynucleotide sequences AAF18425 - AAF18433 and

CC peptide ABP5849 are used in the course of the invention for the

CC identification and characterisation of the polynucleotide and protein

CC sequences.

XX

SQ Sequence 77 AA;

XX

Query Match 11.1%; Score 9; DB 21; Length 77;

Best Local Similarity 100.0%; Pred. No. 0.098;

SQ Sequence 57 AA;

XX

RESULT 13

RESULT 13

KW	Human; chromosome mapping; gene mapping; gene therapy; forensic; food supplement; medical imaging; diagnostic; genetic disorder.
XX	Homo sapiens.
OS	
XX	
PN	WO200175067-A2.
XX	
PD	11-OCT-2001.
XX	
PF	30-MAR-2001; 2001WO-US08631.
XX	
PR	31-MAR-2000; 2000US-0540217.
XX	
PR	23-AUG-2000; 2000US-0649167.
XX	
PA	(HYSE-) HYSEQ INC.
XX	
PT	Drmannac RT, Liu C, Tang YT;
XX	
DR	WPI; 2001-639362/73.
XX	
PS	N-PDB; AAS74681.
XX	
PT	New isolated polynucleotide and encoded polypeptides, useful in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits and to assess biodiversity -
XX	
CC	Claim 20; SEQ ID No 40853; 103pp; English.
XX	
CC	The invention relates to isolated polynucleotide (I) and polypeptide (II) sequences, (I) is useful as hybridisation probes, polymerase chain reaction (PCR) primers, oligomers, and for chromosome and gene mapping, and in recombinant production of (II). The polynucleotides are also used in diagnostics as expressed sequence tags for identifying expressed genes. (I) is useful in gene therapy techniques to restore normal activity of (II) or to treat disease states involving (II). (II) is useful for generating antibodies against it, detecting or quantitating a polypeptide in tissue, as molecular weight markers and as a food supplement. (II) and its binding partners are useful in medical imaging of sites expressing (II). (I) and (II) are useful for treating disorders involving aberrant protein expression or biological activity.
CC	The polypeptide and polynucleotide sequences have applications in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits to assess biodiversity and to produce other types of data and products dependent on DNA and amino acid sequences. ABCG0010-ABG30377 represent novel human diagnostic amino acid sequences of the invention.
CC	Note: The sequence data for this patent did not appear in the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences .
SQ	Sequence 115 AA:
QY	Query Match 11.1%; Score 9; DB 22; Length 115; Best Local Similarity 100.0%; Pred. No. 0.14; Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
20	LGDRARLCL 28
65	LGDRARLCL 73
RESULT 15	
AA96077	
ID	AA96077 standard; Protein: 120 AA.
AC	AA96077;
XX	
DT	21-NOV-2001 (first entry)
XX	
DE	Human reproductive system related antigen SEQ ID NO: 4735.
XX	
KW	Human; reproductive system related antigen; reproductive system disorder; Human; reproductive system related antigen; reproductive system disorder; Homo sapiens.
XX	
PN	WO200153320-A2.
XX	
PD	02-AUG-2001.
XX	
PF	17-JAN-2001; 2001WO-US01339.
XX	
PR	31-JAN-2000; 2000US-0179065.
PR	04-FEB-2000; 2000US-0180628.
PR	24-FEB-2000; 2000US-0184664.
PR	02-MAR-2000; 2000US-0186350.
PR	16-MAR-2000; 2000US-0190076.
PR	17-MAR-2000; 2000US-019076.
PR	18-APR-2000; 2000US-0198123.
PR	19-MAY-2000; 2000US-0205515.
PR	07-JUN-2000; 2000US-0209457.
PR	28-JUN-2000; 2000US-0214886.
PR	30-JUN-2000; 2000US-0215135.
PR	07-JUL-2000; 2000US-0216647.
PR	07-JUL-2000; 2000US-0216880.
PR	11-JUL-2000; 2000US-0217487.
PR	14-JUL-2000; 2000US-0218240.
PR	26-JUL-2000; 2000US-0220954.
PR	14-AUG-2000; 2000US-0224558.
PR	14-AUG-2000; 2000US-0225214.
PR	14-AUG-2000; 2000US-0225266.
PR	14-AUG-2000; 2000US-0225567.
PR	14-AUG-2000; 2000US-0225280.
PR	14-AUG-2000; 2000US-0225419.
PR	14-AUG-2000; 2000US-0225447.
PR	14-AUG-2000; 2000US-0225737.
PR	14-AUG-2000; 2000US-0225758.
PR	14-AUG-2000; 2000US-0225759.
PR	10-AUG-2000; 2000US-0226219.
PR	22-AUG-2000; 2000US-0226681.
PR	22-AUG-2000; 2000US-0227182.
PR	23-AUG-2000; 2000US-0227009.
PR	30-AUG-2000; 2000US-022894.
PR	01-SEP-2000; 2000US-0229207.
PR	01-SEP-2000; 2000US-022934.
PR	01-SEP-2000; 2000US-022934.
PR	01-SEP-2000; 2000US-022945.
PR	05-SEP-2000; 2000US-0229513.
PR	05-SEP-2000; 2000US-0229513.
PR	06-SEP-2000; 2000US-0230438.
PR	08-SEP-2000; 2000US-0231242.
PR	08-SEP-2000; 2000US-023143.
PR	08-SEP-2000; 2000US-023143.
PR	08-SEP-2000; 2000US-023143.
PR	08-SEP-2000; 2000US-023144.
PR	08-SEP-2000; 2000US-0232081.
PR	12-SEP-2000; 2000US-0231968.
PR	14-SEP-2000; 2000US-0232397.
PR	14-SEP-2000; 2000US-0232398.
PR	14-SEP-2000; 2000US-0232399.
PR	14-SEP-2000; 2000US-0232401.
PR	14-SEP-2000; 2000US-0233063.
PR	14-SEP-2000; 2000US-0233064.
PR	21-SEP-2000; 2000US-0234223.
PR	21-SEP-2000; 2000US-0234274.
PR	25-SEP-2000; 2000US-0234957.

PR 25-SEP-2000; 2000US-0234998.
 PR 26-SEP-2000; 2000US-0235484.
 PR 27-SEP-2000; 2000US-0235834.
 PR 29-SEP-2000; 2000US-0236327.
 PR 29-SEP-2000; 2000US-0236367.
 PR 29-SEP-2000; 2000US-0236369.
 PR 29-SEP-2000; 2000US-0236370.
 PR 02-OCT-2000; 2000US-023680.
 PR 02-OCT-2000; 2000US-0237037.
 PR 02-OCT-2000; 2000US-0237038.
 PR 02-OCT-2000; 2000US-0237039.
 PR 02-OCT-2000; 2000US-0237040.
 PR 13-OCT-2000; 2000US-0239935.
 PR 20-OCT-2000; 2000US-0239937.
 PR 20-OCT-2000; 2000US-0240960.
 PR 20-OCT-2000; 2000US-0241122.
 PR 20-OCT-2000; 2000US-0241785.
 PR 20-OCT-2000; 2000US-0241786.
 PR 20-OCT-2000; 2000US-0241787.
 PR 20-OCT-2000; 2000US-0241808.
 PR 20-OCT-2000; 2000US-0241809.
 PR 20-OCT-2000; 2000US-0241826.
 PR 01-NOV-2000; 2000US-0244617.
 PR 08-NOV-2000; 2000US-0244647.
 PR 08-NOV-2000; 2000US-0244675.
 PR 08-NOV-2000; 2000US-0244676.
 PR 08-NOV-2000; 2000US-024477.
 PR 08-NOV-2000; 2000US-024478.
 PR 08-NOV-2000; 2000US-0246523.
 PR 08-NOV-2000; 2000US-0246524.
 PR 08-NOV-2000; 2000US-0246525.
 PR 08-NOV-2000; 2000US-0246526.
 PR 08-NOV-2000; 2000US-0246527.
 PR 08-NOV-2000; 2000US-0246528.
 PR 08-NOV-2000; 2000US-0246532.
 PR 08-NOV-2000; 2000US-0246609.
 PR 08-NOV-2000; 2000US-0246610.
 PR 08-NOV-2000; 2000US-0246611.
 PR 08-NOV-2000; 2000US-0246613.
 PR 17-NOV-2000; 2000US-0246920.
 PR 17-NOV-2000; 2000US-02469209.
 PR 17-NOV-2000; 2000US-02469210.
 PR 17-NOV-2000; 2000US-02469211.
 PR 17-NOV-2000; 2000US-02469212.
 PR 17-NOV-2000; 2000US-02469213.
 PR 17-NOV-2000; 2000US-02469214.
 PR 17-NOV-2000; 2000US-02469215.
 PR 17-NOV-2000; 2000US-02469216.
 PR 17-NOV-2000; 2000US-02469217.
 PR 17-NOV-2000; 2000US-02469218.
 PR 17-NOV-2000; 2000US-0246924.
 PR 17-NOV-2000; 2000US-02469245.
 PR 17-NOV-2000; 2000US-02469264.
 PR 17-NOV-2000; 2000US-02469265.
 PR 17-NOV-2000; 2000US-0246927.
 PR 17-NOV-2000; 2000US-0246929.
 PR 17-NOV-2000; 2000US-0246930.
 PR 01-DEC-2000; 2000US-0250160.
 PR 01-DEC-2000; 2000US-0250391.
 PR 05-DEC-2000; 2000US-0251030.
 PR 05-DEC-2000; 2000US-02511988.
 PR 06-DEC-2000; 2000US-0256719.
 PR 08-DEC-2000; 2000US-0251856.
 PR 08-DEC-2000; 2000US-0251868.
 PR 08-DEC-2000; 2000US-0251869.
 PR 08-DEC-2000; 2000US-0251989.
 PR 11-DEC-2000; 2000US-0251990.
 PR 05-JAN-2001; 2000US-0259678.

XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Rosen CA, Barash SC, Ruben SM;
 XX
 DR WPI: 2001-465570/50.
 DR N-PSDB; AAL02047.
 XX
 Isolated nucleic acid molecule encoding a reproductive system antigen
 PT is used in preventing, treating or ameliorating a medical condition -
 XX
 CC The present invention provides the protein and coding sequences of a
 CC number of human reproductive system related antigens. These can be used
 CC in the prevention and treatment of reproductive system disorders,
 CC including cancer. The present sequence is a protein of the invention.
 XX
 SQ Sequence 120 AA;
 Query Match 11.1%; Score 9; DB 22; Length 120;
 Best Local Similarity 100.0%; Pred. No. 0.14; Mismatches 0;
 Matches 9; Conservative 0; Gaps 0;
 保守性 0; 错配 0;
 Db 20 LGDRRLCL 28
 30 LGDRRLCL 38

Search completed: May 29, 2003, 15:30:40
 Job time : 71 secs